Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
BMJ Case Reports|November 27, 2024
Plasmablastic multiple myeloma presenting as a pleural mass: a diagnostic challengeMaciej Kabat, Vanisha Patel, Pritish BhattacharyyaJournal of Clinical Bioinformatics|April 3, 2015
Clinical decision support systems for improving diagnostic accuracy and achieving precision medicineChristian Castaneda, Kip Nalley, Ciaran Mannion, et al.Journal of Hematology & Oncology|August 31, 2013
Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patientsRajendra Gharbaran, Andre Goy, Takemi Tanaka, et al.Oncotarget|August 27, 2016
Pediatric Hodgkin lymphoma: biomarkers, drugs, and clinical trials for translational science and medicinePoonam Nagpal, Mohamed R Akl, Nehad M Ayoub, et al.American Journal of Hematology|January 26, 2011
Alpha- and beta-synucleins are new diagnostic tools for acute erythroid leukemia and acute megakaryoblastic leukemiaRobert W Maitta, Lucia R Wolgast, Qing Wang, et al.Leukemia & Lymphoma|March 16, 2013
Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphomaAnthony Mato, Tatyana Feldman, Tania Zielonka, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2018
STAG2 Is a Biomarker for Prediction of Recurrence and Progression in Papillary Non-Muscle-Invasive Bladder CancerAlana Lelo, Frederik Prip, Brent T Harris, et al.British Journal of Haematology|March 26, 2014
Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphomaTatyana Feldman, Anthony R Mato, Kar F Chow, et al.Pageof 1